Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Merck
McKinsey
Harvard Business School
Moodys

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR TESTOSTERONE CYPIONATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Testosterone Cypionate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00853502 ↗ The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Withdrawn Massachusetts General Hospital Phase 2 2008-12-01 Decreased bone strength is a common and serious medical problem present in many people with anorexia nervosa. Men with anorexia nervosa have lower levels of gonadal steroids such as testosterone. Low testosterone levels have been shown to result in low bone density. We are investigating whether bone mineral density and bone microarchitecture are abnormal in males with anorexia nervosa and whether supplementation with testosterone would improve both bone mineral density and bone microarchitecture.
NCT00965341 ↗ Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients Completed M.D. Anderson Cancer Center Phase 3 2009-09-01 The goal of this clinical research study is to learn if and how testosterone replacement therapy may affect fatigue in males with advanced cancer and low testosterone levels.
NCT01084759 ↗ A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer Completed Sidney Kimmel Comprehensive Cancer Center N/A 2010-03-01 The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of ≥ 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide. Treatment Plan: Eligible patients will continue on androgen ablative therapy with luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex or Lupron) if not surgically castrated. Patients will receive intramuscular injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This dose was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks. Beginning the day of the testosterone injection, patients will also receive oral etoposide 100 mg/day in divided doses (50 mg q 12h) x 14 days out of 28 days per cycle. After 3 months on therapy, patients will have repeat prostate specific antigen (PSA) and bone/computed tomography (CT) scans to establish the effect of combined testosterone and etoposide treatment on these parameters (i.e. "testosterone effect baseline"). Patients with sustained elevations in PSA ≥ 50% above pre-testosterone treatment PSA levels after the initial three months of testosterone and etoposide therapy will not receive continued therapy and will come off study. Patients with PSA levels less than the peak serum PSA level seen over the three month period (PSA decline) or patients with PSA ≤ 50% of pretreatment baseline will receive a second 3 month course of monthly testosterone and etoposide therapy until evidence of disease progression. Disease progression is defined as a PSA increase above the PSA level obtained after 3 months on testosterone treatment over two successive measurements 2 weeks apart or evidence of new lesions or progression on bone/CT scans compared to baseline studies. Patients who respond to initial treatment with testosterone and etoposide and then show signs of progression will have the option of retreatment with testosterone alone after a period of 3 months or greater off of the original therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Testosterone Cypionate

Condition Name

Condition Name for Testosterone Cypionate
Intervention Trials
Prostate Cancer 7
Hypogonadism, Male 4
Hypogonadism 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Testosterone Cypionate
Intervention Trials
Prostatic Neoplasms 12
Hypogonadism 7
Eunuchism 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Testosterone Cypionate

Trials by Country

Trials by Country for Testosterone Cypionate
Location Trials
United States 40
Brazil 7
Spain 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Testosterone Cypionate
Location Trials
Maryland 9
Massachusetts 5
Washington 3
Texas 3
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Testosterone Cypionate

Clinical Trial Phase

Clinical Trial Phase for Testosterone Cypionate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Testosterone Cypionate
Clinical Trial Phase Trials
Completed 8
Recruiting 7
Not yet recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Testosterone Cypionate

Sponsor Name

Sponsor Name for Testosterone Cypionate
Sponsor Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 9
Sidney Kimmel Comprehensive Cancer Center 5
Brigham and Women's Hospital 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Testosterone Cypionate
Sponsor Trials
Other 33
Industry 4
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim
AstraZeneca
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.